In Rajasthan's Kota district, a spate of maternal deaths over the past two years has reignited scrutiny of the state's obstetric care standards. An in‑depth investigation by India Today reveals that a second drug used during labor—dinoprostone gel—did not meet the required quality benchmarks, compounding concerns that first surfaced with another induction agent.

Background and Scope of the Inquiry

More than 30 pregnant women in Kota have died under circumstances linked to complications during or shortly after delivery. Initial probes identified two drugs—an oxytocin analogue and dinoprostone gel—as possible contributors. While the oxytocin product was already flagged for safety concerns, the latest laboratory results now implicate the dinoprostone gel as equally problematic.

Results of the Quality Assessment

The Rajasthan State Drug Control (SDC) laboratory conducted independent testing and found the active ingredient in the gel to be up to 30% below the pharmacopeial standard. Additional anomalies included unauthorized excipients, inconsistent particle size distribution, and poor stability under normal storage conditions. Such deficiencies not only diminish therapeutic efficacy but also raise the risk of adverse reactions during labor induction.

Regulatory and Administrative Response

Following the findings, the state government issued an immediate recall of all dinoprostone gel batches and suspended its use across public hospitals. At the national level, the Central Drugs Standard Control Organization (CDSCO) elevated the case to a high‑priority investigation, initiating further batch testing and a mandatory re‑certification process.

Systemic Challenges and the Way Forward

The recurrence of two drug‑quality failures in a single maternal‑health crisis underscores systemic weaknesses in India's pharmaceutical supply chain, especially in semi‑urban and rural settings. Experts argue for a multi‑pronged approach: stricter quality control protocols, real‑time tracking of drug shipments, and greater reliance on domestically produced, rigorously vetted medicines. Continuous training for clinicians on drug selection and dosage is also deemed essential to curb preventable deaths.

Voices of Affected Families

Families of the deceased have been vocal in demanding accountability. Beyond seeking legal redress against manufacturers, they are calling for comprehensive reforms in the health delivery system. Several NGOs have amplified the issue, urging the central government to publish transparent audit reports and to strengthen patient‑safety mechanisms.

The Kota investigation serves as a stark reminder that drug safety and regulatory compliance are non‑negotiable pillars for achieving Sustainable Development Goal 3—ensuring healthy lives and promoting well‑being for all. Without decisive action, maternal mortality rates are unlikely to see meaningful decline.